HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Long-lasting clotting factors key step in hemophilia treatment
• Addition of trebananib to paclitaxel extends PFS in recurrent ovarian cancer
• Cancer foundation presents awards
• Epidemiologist joins Cedars-Sinai
• Heart failure patients more likely to receive cancer diagnosis
• Loyola appoints department chair
• Professor to direct ASCO department
• Society officer receives award
• Nephrotic syndrome of unclear etiology hid two primary malignancies Tauseef Sarguroh, MD; Giuseppe Annunziata, MD; Ilmana Fulger, MD
• Health exchange participation growing, but long-term funding remains concern
• Pemetrexed plus erlotinib improved PFS in nonsquamous NSCLC
• High muscle density a prognostic factor in metastatic renal cell carcinoma
• Intermittent iron supplementation appears effective for pregnant women
• 1-year trastuzumab remains standard in HER-2–positive breast cancer
• Barrett’s esophagus recurrence common after RFA, endoscopic mucosal resection
• Circulating BRAF may aid in papillary thyroid cancer diagnosis, follow-up
• Combined factors helped predict positive SLN risk in patients with T1 melanoma
• Coronary heart disease risk associated with colorectal neoplasms
• CV screening recommended for cancer patients receiving chest radiation
• Epoetin-alfa reduced anemia, need for transfusions in high-risk breast cancer
• Higher mortality risk related to thicker single primary melanomas vs. thicker multiple primary melanomas
• Long-term ADT, high-dose radiation improved outcomes in high-risk prostate cancer
• Mortality rate greater among young white males than females with melanoma
• NCI: New databases will aid cancer research
• Oral HPV infections in men less common than genital infections
• Patients at highest risk for lung cancer benefitted most from low-dose CT screening
• Pazopanib effective after progression in metastatic clear-cell RCC
• Prognostic characteristics worse among black patients with CLL
• Radium-223 extended OS, reduced risk for death in castration-resistant prostate cancer
• Recurrence in high-risk bladder cancer warrants intense surveillance
• Reflectance confocal microscopy enhanced treatment of patients with lentigo maligna
• Report provides guidance for ordering vascular lab tests for venous system disorders
• Residual enhancing tumor volume associated with OS, PFS in glioblastoma
• Self-expandable metal stents did not increase pancreaticoduodenectomy complications
• Sex, race determine major risk factors for HCC in older patients
• Stem cell mutations in breast cancer tumors associated with nodal metastases
• Stereotactic ablative radiotherapy extended OS in multiple primary lung cancer
• Study: Nearly half of specialists who remove soft tissue sarcomas are non-oncology-designated surgeons
• Trimodality therapy offers benefit in muscle-invasive bladder cancer
• Thrombosis and anticoagulation: Clinically relevant abstracts from ISTH conference Stephan Moll, MD
• HIV remained undetectable after hematopoietic stem cell transplant
• Next-generation sequencing leads to expanded use of targeted therapies
• Novel gene classifier identifies benign thyroid nodules
• Updated ASCO guideline urges better recognition, management of VTE risk Debbie Blamble, PharmD, BCOP